Dr Nijanth M Raj

Dr Nijanth Manohararaj is a Consultant Neurologist at the National Neuroscience Institute, Singapore General Hospital. He completed his training in Internal Medicine and Neurology in Singapore and holds specialist certification in Neurology from both the Royal College of Physicians, UK and the Specialist Accreditation Board in Singapore. With over 10 years of experience in Singapore's healthcare system, Dr Nijanth is committed to providing compassionate, patient-centered neurological care.

Dr Nijanth serves as Clinical Lead for Headache Services at SGH and is a core member of the Stroke Service. He has a keen interest in innovation and serves as Department Lead for Innovation at NNI (SGH Campus), where he drives initiatives to improve healthcare delivery and patient outcomes through innovative solutions and service redesign.

With a strong passion for research, Dr Nijanth serves as Principal Investigator and Co-Investigator in multiple stroke trials and headache studies, and has been awarded grants for his research work. He is dedicated to medical education and serves as clinical educator for medical students from the Lee Kong Chian School of Medicine (NTU), Yong Loo Lin School of Medicine (NUS), and Duke-NUS Medical School.

Dr Nijanth has received multiple awards recognizing his compassionate patient care and dedication to service quality improvement. His main clinical interests are migraine, headache disorders, and stroke. He has been involved in various initiatives to improve care for these patients across different hospitals within Singapore and actively promotes awareness through public talks and presentations at regional and international conferences.

• ​Consultant, Department of Neurology, National Neuroscience Institute (NNI@SGH)
  
• Fellow, Academy of Medicine, Singapore (Neurology)
  
• Member, International Headache Society
• Member, World Stroke Association
• Member, Clinical Neuroscience Society, Singapore
• Member, Royal College of Physicians, UK
• Member, Singapore Medical Association (SMA)
• Member – NNI, Headache management Workgroup
• Member – NNI, For U NNI (FUN) Wellbeing Committee
• Member - SHAPES – Stroke Healthcare Advocates Professionals & Experts in Singapore
• Member - SNSA – Singapore National Stroke Association
• Clinical Instructor, Duke-NUS Medical School
• Clinical Lecturer, Yong Loo Lin School of Medicine – NUS
• Clinical Educator, Lee Kong Chian School of Medicine – NTU

MINDSET Study (Principal Investigator): Migraine in Singapore: Investigating Determinants of Patients’ Preference for Newer Anti-CGRP Drugs versus Traditional Oral Migraine Preventive Drugs

SEALANT Study (Co-Investigator): Diagnostic challenges and barriers to Migraine Treatment in South East Asia

LIBREXIA - Stroke Trial (Co Investigator): A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

LIBREXIA - AF Trial (Co Investigator): Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

REVIVE Trial (Co-Investigator): A Phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of Redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke

MAPS Trial (Co-Investigator): Missing AF is missing opportunities to Prevent Stroke (MAPS)

MAESTOSO Trial (Co Investigator): A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of MLC1501 in Patients with Stroke

Study Team Member: Burden and Care of Migraine in Singapore

UMPIRE Trial  (Collaborator): Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD - The UMPIRE Randomized Clinical Trial

• Spinal Cord Injury: Extent of disability, its complications and management – An overview for Primary care physicians (2023)